- Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugsAndrew Wagner
Harvard Medical School, Department of Medical Oncology and Ludwig Center for Cancer Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Natl Compr Canc Netw 5:401-10. 2007..As more underlying genetic mechanisms are uncovered, new agents designed to target these lesions will lead to more specific, less toxic, and more effective therapies...
- Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 118:5894-902. 2012..This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors...